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Rabies in humans
 Caused by viruses in genus Lyssavirus
 Acute, progressive encephalomyelitis
 Occurs worldwide
 Nearly always fatal after onset of clinical signs
 Transmitted from infected mammals by bite, 
scratch, or exposure to saliva or neural tissue 
 Not transmitted by exposures to blood, urine, 








Travels centripetally to Central 
Nervous System 
Flows centrifugally to innervated 
organs, including salivary glands 
 Incubation period weeks to months






 Few animal species are reservoirs for rabies





Named for animal reservoir species in which they circulate
Confined to geographically definable regions 
 Infection can be transmitted from the reservoir species 
to other species 
Example, Raccoon RVV can spread from a raccoon 
a cat  a human
RVV does not denote the animal to which the 
human was exposed
Surveillance in United States
 Canine RVV successfully 
eliminated






 Non-terrestrial rabies 
Bats are reservoirs
Endemic in all states 
except Hawaii
 ~5,000 animals test 
positive for rabies / year
Skunk RVV: Orange = South central, Blue = 
North central, Brown = California; Fox RVV: Red 
= Arctic fox, Hash = Gray fox; Raccoon RVV: 
Green; Mongoose RVV: Yellow.
Exposures that have led to confirmed 









Occupational including laboratory work
Contacts in everyday life
• Bats in home
• Residence in wooded areas with increased opportunities for 
contact
Organ and tissue transplants
 International travel
Leisure and occupational animal exposures
Dogs are most important animal reservoir
Human rabies—United States, 2009-2019 
(N=25)
 ~2-4 cases / year








3 raccoon RVV (including kidney donor and recipient)
1 mongoose RVV
1 unknown RVV
 International exposures (n=8)
7 dog  RVV(Philippines, Guatemala, Brazil, Afghanistan, Haiti, India)
1 bat RVV (Mexico)
 None due to occupational exposures
Prevention of human rabies
 Primary prevention:  Avoiding animal exposures, 






• >15,000 people receive PrEP / year in U.S.
Post-exposure prophylaxis (PEP)
• Washing wound with soap and water, rabies immune globulin, 
vaccine series
• 50,000 people receive rabies PEP / year in U.S. 
 None of the confirmed cases in the last 10 years 
received PrEP or PEP
Factors that contribute to PrEP and PEP 
recommendations





Decision to administer PEP






Is the exposure a bite or non-bite (i.e., aerosol, organ / 
tissue transplant, contamination of wounds or mucous 
membranes with saliva or neural tissue)?
Is the exposure to urine, feces, skin, or blood? 
 Bio-Geo-Behavioral Risk Assessment
Is the animal a reservoir species for rabies?
What is the rabies epidemiology in the area?
Was the animal showing signs of rabies?
Schedules and Titer Checks for PEP
 Was PrEP administered?
 Were there any deviations in PEP administration?
 Does the patient require special considerations? Example 
immunocompromised?
National and global rabies 
recommendations and products
Timeline of recent national and global 
recommendations for PrEP and PEP schedules
2008               2010                                             2018               2019
Remote U.S. rabies management:
Impaired vaccine quality 
Decreased potency
Increased adverse events
Intradermal and Intramuscular licensed vaccines
Large number of vaccines for PEP
Timeline of recent national and global 
recommendations for PrEP and PEP schedules in 
healthy, nonpregnant persons
2008               2010                                             2018               2019
ACIP: PEP IM[5 dose series]
Timeline of recent national and global 
recommendations for PrEP and PEP schedules in 
healthy, nonpregnant persons
2008               2010                                             2018               2019
Prompted by vaccine shortage, data was reviewed
ACIP: PEP IM[4 dose series]
Timeline of recent national and global 
recommendations for PrEP and PEP schedules in 
healthy, nonpregnant persons
2008               2010                                             2018               2019
WHO reviewed data.  
New recommendations 
IM and ID
Timeline of recent national and global 
recommendations for PrEP and PEP schedules in 
healthy, nonpregnant persons
2008               2010                                             2018         2019/2020
ACIP ?
Vaccines and human immunoglobulins licensed in U.S.
Biologic Product 
name
Manufacturer Licensed for 
Administration
Human diploid cell vaccine
(HDCV)
Imovax® Sanofi Pasteur Intramuscularly
Purified chick embryo cell 
vaccine (PCECV)
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